Interactions between inflammation and coagulation in autoimmune and immune-mediated skin diseases

Current Vascular Pharmacology

Volumn 10, Issue 5, 2012, Pages 647-652

  Marzano, Angelo V ^a   Tedeschi, Alberto ^b   Polloni, Ilaria ^a   Crosti, Carlo ^a   Cugno, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Atopic dermatitis; Bullous pemphigoid; Dermatitis herpetiformis; Eosinophil; Psoriasis; Tissue factor

Indexed keywords

ARTICLE; ATOPIC DERMATITIS; AUTOIMMUNE SKIN DISEASE; BLOOD CLOTTING; BULLOUS PEMPHIGOID; DERMATITIS HERPETIFORMIS; HUMAN; IMMUNE MEDIATED SKIN DISORDER; INFLAMMATION; PSORIASIS; SKIN DISEASE; THROMBOSIS;

AGE FACTORS; ANTICOAGULANTS; AUTOIMMUNE DISEASES; BLOOD COAGULATION; CARDIOVASCULAR DISEASES; CONTROLLED CLINICAL TRIALS AS TOPIC; HUMANS; INFLAMMATION; RISK FACTORS; SKIN DISEASES; THROMBOSIS;

EID: 84864538752     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016112801784567     Document Type: Article

References (49)

1. Opal SM. Phylogenetic and functional relationships between coagulation and the innate immune response. Crit Care Med 2000; 28 Suppl: S77-S80.
2. Levi M, van der Poll T. Two-way interactions between inflammation and coagulation. Trends Cardiovasc Med 2005; 15: 254-9
3. Yancey KB. The pathophysiology of autoimmune blistering diseases. J Clin Invest 2005 115: 825-8.
4. Yancey KB, Egan CA. Pemphigoid: clinical, histologic, immunopathologic, and therapeutic considerations. JAMA 2000; 284: 350-6.
5. Marzano AV, Vezzoli P, Colombo A, Serini SM, Crosti C, Berti E. Peristomal bullous pemphigoid. J Dermatol 2010; 37: 840-2.
6. Ujiie H, Shibaki A, Nishie W, Shimizu H What's new in bullous pemphigoid. J Dermatol 2010; 37: 194-204.
7. Schmidt E, Zillikens D. Autoimmune and inherited subepidermal blistering diseases: advances in the clinic and the laboratory. Adv Dermatol 2000; 16: 113-57.
8. Hertl M, Eming R, Veldman C. T cell control in autoimmune bullous skin disorders. J Clin Invest 2006; 116: 1159-66.
9. Frezzolini A, Cianchini G, Ruffelli M, Cadoni S, Puddu P, De Pita O. Interleukin-16 expression and release in bullous pemphigoid. Clin Exp Immunol 2004; 137: 595-600.
10. Ameglio F, D'Auria L, Bonifati C, Ferraro C, Mastroianni A, Giacalone B. Cytokine pattern in blister fluid and serum of patients with bullous pemphigoid: relationships with disease intensity. Br J Dermatol 1998; 138: 611-4.
11. Borrego L, Maynard B, Peterson EA, et al. Deposition of eosinophil granule proteins precedes blister formation in bullous pemphigoid. Comparison with neutrophil and mast cell granule proteins. Am J Pathol 1996; 148: 897-909.
12. Frezzolini A, Teofoli P, Cianchini G, et al. Increased expression of eotaxin and its specific receptor CCR3 in bullous pemphigoid. Eur J Dermatol 2002; 12: 27-31.
13. Niimi Y, Pawankar R, Kawana S. Increased expression of matrix metalloproteinase-2, matrix metalloproteinase-9 and matrix metalloproteinase-13 in lesional skin of bullous pemphigoid. Int Arch Allergy Immunol 2006; 139: 104-113.
14. Shimanovich I, Mihai S, Oostingh GJ, et al. Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid. J Pathol 2004; 204: 519-27.
15. Ståhle-Bäckdahl M, Inoue M, Guidice GJ, Parks WC. 92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kD bullous pemphigoid autoantigen. J Clin Invest 1994; 93: 2022-30.
16. Marzano AV, Tedeschi A, Fanoni D, et al. Activation of blood coagulation in bullous pemphigoid: role of eosinophils, and local and systemic implications. Br J Dermatol 2009; 160: 266-72.
17. Moosbauer C, Morgenstern E, Cuvelier SL, et al. Eosinophils are a major intravascular location for tissue factor storage and exposure. Blood 2007; 109: 995-1002.
18. Marzano AV, Tedeschi A, Spinelli D, Fanoni D, Crosti C, Cugno M. Coagulation activation in autoimmune bullous diseases. Clin Exp Immunol 2009; 158: 31-6.
19. Marzano AV, Tedeschi A, Berti E, Fanoni D, Crosti C, Cugno M. Activation of coagulation in bullous pemphigoid and other eosinophil-related inflammatory skin diseases. Clin Exp Immunol 2011; 165: 44-50.
20. Garcia JG, Siflinger-Birnboim A, Bizios R, Del Vecchio PJ, Fenton JW 2nd, Malik AB. Thrombin-induced increase in albumin permeability across the endothelium. J Cell Physiol 1986; 128: 96-104.
21. DeMichele MA, Moon DG, Fenton JW 2nd, Minnear FL. Thrombin's enzymatic activity increases permeability of endothelial cell monolayers. J Appl Physiol 1990; 69: 1599-606.
22. Rosendaal FR, Van Hylckama Vlieg A, Doggen CJM. Venous thrombosis in the elderly. J Thromb Haemost 2007; 5 (Suppl 1): 310-7.
23. Darsow U, Wollenberg A, Simon D, et al.; European Task Force on Atopic Dermatitis/EADV Eczema Task Force. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2010; 24: 317-28.
24. Reid SD, Penna G, Adorini L. The control of T cell responses by dendritic cell subsets. Curr Opin Immunol 2000; 12: 114-21.
25. Niebuhr M, Langnickel J, Draing C, Renz H, Kapp A, Werfel T. Dysregulation of toll-like receptor-2(TLR-2)-induced effects in monocytes from patients with atopic dermatitis: impact of the TLR-2 R753Q polymorphism. Allergy 2008; 63: 728-34.
26. Ito Y, Satoh T, Takayama K, Miyagishi C, Walls AF, Yokozeki H. Basophil recruitment and activation in inflammatory skin diseases. Allergy 2011; 66: 1107-13.
27. Zhang B, Alysandratos KD, Angelidou A, et al. Human mast cell degranulation and preformed TNF secretion require mitochondrial translocation to exocytosis sites: relevance to atopic dermatitis. J Allergy Clin Immunol 2011; 127: 1522-31.
28. Jung T, Stingl G. Atopic dermatitis: therapeutic concepts evolving from new pathophysiologic insights. J Allergy Clin Immunol 2008; 122: 1074-81.
29. Hamid Q, Boguniewicz M, Leung DY. Differential in situ cytokine gene expression in acute vs. chronic atopic dermatitis. J Clin Invest 1994; 94: 870-6.
30. Hamid Q, Naseer T, Minshall EM, Song YL, Boguniewicz M, Leung DY. In vivo expression of IL-12 and IL-13 in atopic dermatitis. J Allergy Clin Immunol 1996; 98: 225-31.
31. Powrie F, Correa-Oliveira R, Mauze S, Coffman RL. Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J Exp Med 1994; 179: 589-600.
32. Maggi L, Santarlasci V, Liotta F, et al. Demonstration of circulating allergen-specific CD4+CD25highFoxp3+ T-regulatory cells in both non-atopic and atopic individuals. J Allergy Clin Immunol 2007; 120: 429-36.
33. Verhagen J, Akdis M, Traidl-Hoffmann C, et al. Absence of Tregulatory cell expression and function in atopic dermatitis skin. J Allergy Clin Immunol 2006; 117: 176-83.
34. Leung DYM, Bieber T. Atopic dermatitis. Lancet 2003; 361: 151-60.
35. Nastałek M, Wojas-Pelc A, Undas A. Plasma fibrin clot properties in atopic dermatitis: links between thrombosis and atopy. J Thromb Thrombolysis 2010; 30: 121-6.
36. Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-71.
37. Shelling ML, Federman DG, Prodanovich S, Kirsner RS. Psoriasis and vascular disease: an unsolved mystery. Am J Med 2008; 121: 360-5.
38. Schön MP, Boehncke WH. Psoriasis. N Engl J Med 2005; 352: 1899-912.
39. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361: 496-509.
40. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-41.
41. Marongiu F, Sorano GG, Bibbò C, et al. Abnormalities of blood coagulation and fibrinolysis in psoriasis. Dermatology 1994; 189: 32-7.
42. Karabudak O, Ulusoy RE, Erikci AA, Solmazgul E, Dogan B, Harmanyeri Y. Inflammation and hypercoagulable state in adult psoriatic men. Acta Derm Venereol 2008; 88: 337-40.
43. Bolotin D, Petronic-Rosic V. Dermatitis herpetiformis. Part I. Epidemiology, pathogenesis, and clinical presentation. J Am Acad Dermatol 2011; 64: 1017-24.
44. Marietta E, Black K, Camilleri M, et al. A new model for dermatitis herpetiformis that uses HLA-DQ8 transgenic NOD mice. J Clin Invest 2004; 114: 1090-7.
45. Mobacken H, Kastrup W, Nilsson LA. Incidence and prevalence of dermatitis herpetiformis in Sweden. Arch Derm Venereol 1984; 64:400-4.
46. Caproni M, Antiga E, Melani L, Fabbri P; Italian Group for Cutaneous Immunopathology. Guidelines for the diagnosis and treatment of dermatitis herpetiformis. J Eur Acad Dermatol Venereol 2009; 23: 633-8.
47. Patrício P, Ferreira C, Gomes MM, Filipe P. Autoimmune bullous dermatoses: a review. Ann N Y Acad Sci 2009; 1173: 203-10.
48. Caproni M, Cardinali C, D'Agata A, Selvaggi W, Fabbri P. Serum eosinophil cationic protein, myeloperoxidase, tryptase, eotaxin and Th2-L-like cytokines in dermatitis herpetiformis. Int Arch Allergy Immunol 2002; 128: 67-72.
49. Cox NH, Friedmann PS. Induction of lesions of dermatitis herpetiformis by autologous serum. Br J Dermatol 1991; 124: 69-73.